Our news journalists obtained a quote from the research, "A disulfide rebridging reagent comprising monomethyl auristatin E (MMAE) was prepared and conjugated to trastuzumab (TRA). A 78% conversion of antibody to ADC with a drug to antibody ratio (DAR) of 4 was achieved with no unconjugated antibody remaining. The MMAE rebridging reagent was also conjugated to the interchain disulfide of a Fab derived from proteolytic digestion of TRA, to give a homogeneous single drug conjugated product. The resulting conjugates retained antigen-binding, were stable in serum, and demonstrated potent and antigen-selective cell killing in in vitro and in vivo cancer models."
According to the news editors, the research concluded: "Disulfide rebridging conjugation is a general approach to prepare stable ADCs, which does not require the antibody to be recombinantly re-engineered for site-specific conjugation."
For more information on this research see: Bridging Disulfides for Stable and Defined Antibody Drug Conjugates. Bioconjugate Chemistry, 2014;25(6):1124-1136. Bioconjugate Chemistry can be contacted at: Amer Chemical Soc,
The news correspondents report that additional information may be obtained from G. Badescu,
Keywords for this news article include: Ions, Antibodies, London,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Hispanic Leader Goes the Extra Mile
- Ted Cruz: Why Did FAA Ban Flights to Israel?
- Morgan Stanley Ponies Up $275 Million to Settle SEC Charges
- Stop-Start Engines Save Gas, Reduce Emissions
- Risks of Layoffs Becoming Rarer in U.S.
- Weekly Jobless Claims Drop to Lowest Level in 8 Years
- Shia LaBeouf Plea Deal, Alcoholism Treatment
- Ricky Martin Joins 'The Voice ... Mexico'
- Ohio State Band Chief Fired After Probe
- Jennifer Lopez, Pitbull to Perform at Fashion Rocks